Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab for acute gouty arthritis (phase II dose-finding)
CTR20213164Phase 2Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of genakumab in acute gout flare (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of genakumab and Dose–response of genakumab on target joint pain at 72 hours. Started Dec 2021; status: completed.
02
Drugs
genakumab
03
Conditions
acute gout flare
Beyond the preview
Go deeper on CTR20213164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213164.